Teva Pharmaceutical Industries Limited (NYSE:TEVA) does about 9.76M shares in volume on a normal day but saw 14709632 shares change hands in Monday trading. The company now has a market cap of 11.55B USD. Its current market price is $10.38, marking a decrease of -0.29% compared to the previous close of $10.41. The 52 week high reached by this stock is $11.44 whilst the lowest price level in 52 weeks is $6.78. The script in recent trading has seen the stock touch a high of $10.47 and a low of $10.23.
Teva Pharmaceutical Industries Limited (TEVA) has a 20-day trading average at $10.21 and the current price is -9.31% off the 52-week high compared with 53.12% distance from its 52-week low. The 50-day simple moving average of the closing price is $9.38 and its 200-day simple moving average is $8.88. If we look at the stock’s price movements over the week, volatility stands at 2.59%, which increases to 3.48% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 56.45 to suggest the stock is neutral.
13 analysts observing the Teva Pharmaceutical Industries Limited (TEVA) stock have set the 12-month price targets for the company’s shares at between $7.00 and $13.00. The consensus objective for the share price is $10.00, suggesting that the stock has a potential downside of -3.8% over the period. The median price target is -3.8% away from the current levels at $10.00.
FactSet Research has provided data showing that 13 brokerages have issued ratings for the stock. 3 analysts have rated it as a sell, while 1 advise that it is a overweight. 2 analysts have rated it as a buy and 7 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Hold the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 19, 2023 when Jefferies downgraded the stock to “Hold” and issued a price target of between $10 and $12. JP Morgan also downgraded the stock to “Underweight” from Neutral on November 14, 2022 at a price target of $11-$10.
The current price level is 2.46%, 10.98%, and 16.96% away from its SMA20, SMA50, and SMA200 respectively, with the TEVA price moving below the 50-day SMA on January 23. Teva Pharmaceutical Industries Limited (TEVA) stock is down -7.65% over the week and 19.45% over the past month. Its price is 13.82% year-to-date and 20.14% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of $0.59 below consensus estimates by -$0.03. The company’s next earnings report is expected on 05/04/2023, with forecasts estimating quarterly EPS at $0.71 and $2.48 for whole year. TEVA’s earnings per share are forecast to shrink by -3.90% this year and 1.20% over next year. Expected sales for next quarter are $3.55 billion, which analysts say will come at $15.12 billion for the current fiscal year and next year at $15.22 billion. In addition, estimates put the company’s current quarterly revenue at an average of $3.92 billion.
Its 12-month price target is $10.00. To reach the target analysts have set, the stock logically needs to shrink -3.8 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $7.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $13.00.
Outstanding shares total 1.11B with insiders holding 1.88% of the shares and institutional holders owning 49.60% of the company’s common stock. The company has a return on investment of 4.50% and return on equity of -13.80%. The forward price to earnings ratio is 4.14. The beta has a value of 1.20. Price to book ratio is 1.32 and price to sales ratio is 0.76.
American Funds Growth Fund of Ame isn’t the only investment manager who changed stakes and is followed by American Funds Investment Company, which sold off -2.37 million shares to end up with 54,424,650 shares worth $496.35 million. American Funds Fundamental Invest raise their holdings by 28.52% in the company over the course of the most recent quarter. It now holds a 2.05% position in Teva Pharmaceutical Industries Limited thanks to 22.73 million shares amounting to $207.31 million.